N-Acetylcysteine Dosing for Drug-Induced Liver Injury (DILI)
For non-acetaminophen drug-induced liver injury, administer intravenous NAC using the standard acetaminophen overdose protocol: 150 mg/kg loading dose over 15 minutes, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (21-hour protocol). 1
Evidence for NAC in Non-Acetaminophen DILI
The use of NAC extends beyond acetaminophen toxicity to other forms of drug-induced hepatic failure, with demonstrated mortality benefit:
- NAC improves transplant-free survival in non-acetaminophen acute liver failure from 30% to 41% (OR = 1.61,95% CI 1.11–2.34, P = 0.01) 1
- Overall survival increases from 59% to 76% (OR = 2.30,95% CI 1.54–3.45, P <0.0001) in adult patients with non-acetaminophen liver failure 1
- Liver transplant-free survival improves from 26% to 64% (OR = 4.81,95% CI 3.22–7.18, P < 0.0001) 1
Initiation and Timing
Start NAC immediately upon suspicion of drug-induced hepatic failure without waiting for confirmatory laboratory results. 1 The beneficial effects appear greatest in patients with early-stage hepatic encephalopathy (grades I-II), making prompt initiation critical 1.
Key Clinical Scenarios Requiring NAC:
- Any suspected drug-induced acute liver failure, regardless of the causative agent 1
- Elevated transaminases with suspected DILI, even when the specific drug cannot be identified 1
- Acute liver failure of uncertain etiology, as NAC has minimal toxicity and potential benefit 1
Standard Dosing Protocol
Intravenous Administration (Preferred):
- Loading dose: 150 mg/kg in 5% dextrose over 15 minutes 1
- Second dose: 50 mg/kg over 4 hours 1
- Third dose: 100 mg/kg over 16 hours 1
- Total duration: 21 hours 1
Oral Administration (Alternative):
- Loading dose: 140 mg/kg by mouth or nasogastric tube 1
- Maintenance: 70 mg/kg every 4 hours for 17 doses 1
- Total duration: 72 hours 1
Monitoring During Treatment
Monitor the following parameters throughout NAC therapy:
- Liver function tests: AST, ALT, alkaline phosphatase, and total bilirubin 1
- Coagulation parameters: INR and PT to assess treatment response 1
- Clinical status: Mental status changes, signs of hepatic encephalopathy 1
Duration of Treatment
Unlike acetaminophen overdose where treatment can be stopped based on specific laboratory criteria, non-acetaminophen DILI typically requires completion of the full 21-hour IV protocol or consideration of extended treatment based on clinical response. 1 Continue NAC if:
- Transaminases remain elevated or continue rising 1
- Coagulopathy persists (elevated INR) 1
- Clinical signs of hepatic failure are present 1
Adverse Effects and Management
Common adverse effects occur but are generally manageable:
- Nausea and vomiting: Most common, particularly with oral administration 1
- Skin rash: Occurs in <5% of patients 1
- Transient bronchospasm: Occurs in 1-2% of patients 1
- Anaphylactoid reactions: More common with IV administration, typically during the loading dose 2
These adverse effects should not delay or prevent NAC administration in the setting of acute liver failure. 1
Critical Pitfalls to Avoid
Do not delay NAC administration while awaiting:
- Confirmatory drug levels or toxicology screens 1
- Liver biopsy results 1
- Determination of the specific causative agent 1
The decision to treat should be based on clinical suspicion and evidence of acute liver injury, not on definitive diagnosis of the causative drug. 1 Delaying treatment reduces efficacy and worsens outcomes 1.
Special Considerations
The quality of evidence for NAC in non-acetaminophen DILI is lower than for acetaminophen-induced cases, but the demonstrated mortality benefit and minimal toxicity support its use 1. Some guidelines recommend NAC only in clinical trial settings for non-acetaminophen cases, though recent evidence increasingly supports broader use 1.
For patients with severe hepatotoxicity (AST >1000 IU/L) or coagulopathy, ICU-level care and early transplant hepatology consultation are essential, as NAC is an adjunct to comprehensive supportive care 3.